P683: TRIALS IN PROGRESS: FIRST-IN-HUMAN STUDY OF ELVN-001, A SELECTIVE BCR::ABL1 TYROSINE KINASE INHIBITOR, IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO FAILED PREVIOUS TYROSINE KINASE INHIBITOR THERAPIES
Fabian Lang,
Susan Branford,
Joseph P. Lyssikatos,
Helen Collins,
Andreas Hochhaus
Affiliations
Fabian Lang
1 Klinikum der Goethe Universitat, Frankfurt, Germany
